Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA(0)-Tyr(3)-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors

PURPOSE: Peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA(0)-Tyr(3)-octreotate ((177)Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression. We have, for the first time, reported the results o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Noritoshi, Takano, Shoko, Ito, Kenichi, Sugiura, Madoka, Ogawa, Matsuyoshi, Takeda, Yuma, Okubo, Naoki, Suzuki, Akihiro, Tokuhisa, Motohiko, Kaneta, Tomohiro, Utsunomiya, Daisuke, Hata, Masaharu, Inoue, Tomio, Hosono, Makoto, Kinuya, Seigo, Ichikawa, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557155/
https://www.ncbi.nlm.nih.gov/pubmed/34533700
http://dx.doi.org/10.1007/s12149-021-01674-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557155/
https://www.ncbi.nlm.nih.gov/pubmed/34533700
http://dx.doi.org/10.1007/s12149-021-01674-9

Ejemplares similares